CELL INTELLIGENCE · 肿瘤细胞治疗研究

通过 ATRA、硼替佐米与 NK 细胞联合治疗克服 CD44 高表达骨髓瘤的耐药

Overcoming resistance in CD44-overexpressing myeloma through combination therapy with ATRA, bortezomib, and NK cells.

基于 FAERS 数据的靶向 B 细胞成熟抗原免疫治疗中细胞因子释放综合征的信号检测与机器学习预测

Signal Detection and Machine Learning-Based Prediction of Cytokine Release Syndrome in B-Cell Maturation Antigen-Targeting Immunotherapies Using FAERS

多发性骨髓瘤中 BCMA 的生物学与治疗靶向：从配体信号到抗原逃逸

BCMA biology and therapeutic targeting in multiple myeloma: From ligand signaling to antigen escape.

靶向复发/难治性多发性骨髓瘤中的 B 细胞成熟抗原：即将迎来其黄金时期

Targeting B-cell maturation antigen in relapsed or refractory multiple myeloma: On the verge of its prime time.

CAR-T 细胞疗法在实体瘤中的挑战与局限：为何获批仅限于血液系统恶性肿瘤？

Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies?

肿瘤预激 CD8⁺ 自然杀伤 T 样细胞作为复发/难治性多发性骨髓瘤的高效新型细胞疗法

Tumor-priming CD8(+) natural killer T-like cells as an efficient novel cell therapy for relapsed/refractory multiple myeloma.

TPNC 是一种通过肿瘤驱动的致敏产生的新型细胞毒性淋巴细胞产品。

复发/难治性多发性骨髓瘤临床实践中基于抗 CD38 治疗的共识指南与推荐：来自泛太平洋多发性骨髓瘤工作组

Consensus Guidelines and Recommendations for the anti-CD38-based Therapy in Clinical Practice for Relapsed/Refractory Multiple Myeloma: From the Pan-P

扩增并激活的骨髓浸润淋巴细胞对自体多发性骨髓瘤细胞表现出强效的抗骨髓瘤活性

Expanded and activated marrow-infiltrating lymphocytes exhibit potent antimyeloma activity against autologous multiple myeloma cells.

达雷妥尤单抗单药治疗及后续治疗在重度经治复发/难治多发性骨髓瘤中的成本-效果分析：一种使用韩国全国人群队列的可行方法学

Cost-Effectiveness Analysis of Daratumumab Monotherapy and Subsequent Therapies in Heavily Treated Relapsed/Refractory Multiple Myeloma: A Feasible Me

本研究提供了一个新的成本效果框架，将治疗效果与现实世界成本联系起来，支持对未来 MM 疗法的社会成本进行预测。

双份脐血与单倍体供者移植在成人急性淋巴细胞白血病患者中的长期结局比较：关于 KIR 配体错配

Comparison of Long-Term Outcomes of Double Unit Cord Blood Versus Haploidentical Donor Transplantation in Adult Patients With Acute Lymphoblastic Leuk

我们的研究支持 DCBT 在 HIDT 主导时代的有用性，并提示了改善 DCBT 生存结局的潜在途径。